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Abstract
Background: Mycobacterium xenopi-infected patients have a high prevalence of pulmonary cavities and nodules.
However, the clinical course for patients with miliary nodules due to M. xenopi has not yet been reported.
Case presentation: We encountered a case of miliary nodules with gradually worsening coughing and sputum
production in a 44-year-old male who had renal dysfunction due to glomerulosclerosis with a decade-long history
of steroid therapy. Although we started anti-tuberculosis treatment on clinical suspicion of miliary tuberculosis,
cultures of sputum and bronchial lavage were both positive for M. xenopi. The patient was successfully treated with
rifampin, ethambutol and clarithromycin, without fibrosis. It was unclear whether the miliary pattern was induced
by hematogenous or endobronchial spread of the M. xenopi infection.
Conclusion: Even when clinical and radiological disease manifestations are similar to those of miliary tuberculosis,
M. xenopi infection should be considered in the differential diagnosis of miliary nodules.
Keywords: Mycobacterium xenopi, Miliary nodules, Immunocompromised patient
Background
Mycobacterium xenopi is one of the common causes of
nontuberculous mycobacteria (NTM) pulmonary disease,
especially in Canada, France and the United Kingdom
[1–3]. In comparison with M. avium complex (MAC),
M. xenopi-infected patients were found to have a high
prevalence of pulmonary cavities and nodules, and
rarely present a nodular bronchiectatic form [4]. A
large number of patients with pulmonary cavities due
to M. xenopi simultaneously had computed tomography
(CT) findings of random nodules or consolidation rather
than the fibrocavitary form [4]. The management of
individual patients with M. xenopi is difficult, since a
standard treatment has not been established.
Regarding the random nodules, 4 cases of miliary
nodules due to M. xenopi with acquired immunodefi-
ciency syndrome were reported by Bankier et al. How-
ever, the radiological evaluation of these cases was made
by chest X-ray, not by CT. In addition, the clinical
course for the patients was not described [5]. In this
report, we present a case of chest CT-proven miliary
nodules due to M. xenopi without cavities and consolida-
tions in a steroid-induced immunocompromised patient
successfully treated with chemotherapy.
Case presentation
A 44-year-old male, who had renal dysfunction due to
glomerulosclerosis with a decade-long history of steroid
therapy (10–20 mg of prednisone per day), visited our
department because of gradually worsening coughing
and sputum production. He had no past history of any
pulmonary disease, such as chronic obstructive pulmon-
ary disease (COPD), tuberculosis or bronchial asthma.
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The results of a physical examination were normal.
Laboratory data were as follows: white blood cell count,
10630/μl (neutrophils, 91.6 %); hemoglobin, 12.5 g/dl;
platelet count, 61.2 x 104/µl; C-reactive protein,
6.27 mg/dl; creatinine, 1.64 mg/dl. Chest X-ray and CT
showed a high number of miliary nodules in both lungs
without consolidations or cavities (Fig. 1a and b). Under-
lying pulmonary diseases, such as emphysema and bron-
chiectasis, were not observed. Abdominal CT and
magnetic resonance imaging of the spine detected no
extrapulmonary lesions. Although a sputum acid-fast ba-
cillus smear was positive, polymerase chain reaction
(PCR) tests for M. tuberculosis, M. avium and M. intracel-
lurare of the sputum were all negative. On clinical suspi-
cion of miliary tuberculosis, we started quadruple therapy
(isoniazid, rifampin (RFP), ethambutol (EB) and pyrazina-
mide) without dose reduction of prednisone (10 mg/day).
Then, we carried out a bronchoscopic examination, and
transbronchial lung biopsy detected small granuloma
(Fig. 1c and d) and Ziehl-Neelsen staining-positive bacillus
bodies (Fig. 1e). Acid-fast bacillus smear and PCR tests of
bronchial lavage showed the same results as sputum.
Later, the culture of sputum and bronchial lavage obtained
mycobacterium colonies, and the isolates from both
samples were identified as M. xenopi by DNA-DNA
hybridization (DDH). Since patients infected with M.
heckeshornense may have been included in the cases that
were diagnosed as M. xenopi disease by DDH, we
reconfirmed that the isolate from bronchial lavage was M.
xenopi by sequence analyses of the 16S rRNA gene, rpoB
and hsp65 [6]. After the final diagnosis of M. xenopi
pulmonary infection was established, we changed the
quadruple therapy to treatment with RFP (450 mg/day),
EB (750 mg/day) and clarithromycin (CAM) (800 mg/
day). Chemotherapy was continued for a total period of
15 months without side effects, and steroid therapy for
glomerulosclerosis was also continued without dose modi-
fication. Sputum cultures yielded no mycobacteria in the
last 12 months. After the chemotherapy, chest CT showed
a prominent reduction in the size and number of miliary
nodules without fibrosis (Fig. 1f).
Discussion
Clinical and radiological disease manifestations of M.
xenopi infection vary according to each person’s immuno-
logical status, and can be classified into three groups: (1)
a cavitary form in patients with pre-existing pulmonary
disease; (2) a solitary nodular form in immunocompetent
patients and (3) an acute infiltrate form in immunosup-
pressed patients [2]. Although multiple small nodules
(<5 mm) coexisting with a predominant form were a
common finding in patients with M. xenopi pulmonary
infection, the mean number is about 10–16 per patient
[4, 7]. Therefore, the CT-proven miliary pattern without
cavities and consolidations observed in our immuno-
compromised patient could be a distinct entity.
Previously, O’Connell et al. reported an autopsy-based
series of pulmonary or disseminated nontuberculous
mycobacterial disease. In that report, a miliary pattern was
noted in 2 of the 5 disseminated patients with myco-
bacterial lung involvement, but not in the 11 primary
pulmonary mycobacterial diseases without extrapulmonary
Fig. 1 Chest X-ray (a), CT (b and f) and pathological findings of transbronchial lung biopsy (c and d, hematoxylin and eosin staining;
e, Ziehl-Neelsen staining). a and b: A high number of miliary nodules in both lungs without consolidations and cavities at presentation.
c and d: Granulomatous inflammation (c, low-power field; d, high-power field). e: Bacillus bodies seen as a bright red rod. f: Marked improvement
in miliary nodules after 15 months of chemotherapy
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infection [8]. In addition, miliary pulmonary infection with
a macropapular rash on extremities caused by M. terrae in
an immunocompromised patient was reported [9]. Miliary
pulmonary infection due to nontuberculous mycobacteria
in a patient without extrapulmonary infections may be
extremely rare.
Although a miliary pattern is usually induced by the
hematogenous spread of infection or tumor cells, this
pattern with or without ground-glass opacities sometimes
can be seen in so-called hot tub lung (HTL) caused by
inhalation of water aerosol containing NTM, especially
the MAC [10–12]. There seems to be quite a controversy
over whether HTL is a direct appearance of mycobacterial
infection or is a hypersensitivity pneumonitis (HP).
Because the sputum cultures continued to be positive for
6 weeks after initiation of chemotherapy, an infectious
process was probably involved in the pathogenesis in our
case. While acid-fast bacillus cultures of sputum, tissue
and bronchial lavage from patients with HTL are positive
at high rates, HTL usually manifests spontaneous or
steroid-induced improvement after cessation of hot tub
exposure without antimycobacterial treatment [12]. It was
also reported in a mouse model that HTL develops
through mycobacterial engagement with Toll-like receptor
9/Myeloid differentiation factor 88 signaling in pulmonary
CD11b-positive dendritic cells, regardless of the myco-
bacterial infectious capacity [13]. In addition, intravesical
administration of bacillus Calmette-Guerin (BCG) against
urothelial cancer occasionally induces systemic hypersen-
sitivity reactions, including pneumonitis, without detec-
tion of BCG in corresponding organs [14]. These data
indicate that NTMs have pathogenic potential not only as
infectious microorganisms, but also as highly immuno-
genic substances for HP. Although HTL generally appears
in immunocompetent patients with no preexisting lung
disease [12], the hypersensitivity phenomenon may have
overlapped, to a greater or lesser degree, with an infec-
tious process in the pathogenesis in our case. From the
above-mentioned points, the possibility remains that the
miliary pattern of our patient resulted from endobronchial
spread of the M. xenopi infection with hypersensitivity to
M. xenopi antigens.
Although a standard treatment for M. xenopi has not
been established, ATS/IDSA recommends an RFP, EB
and CAM-containing regimen [15]. In general, the prog-
nosis for the hematogenous spread of infection in
immunocompromised patients is poor, but a prognosis
for NTM miliary infection has not been well docu-
mented. In this case, treatment with RFP, EB and CAM
was effective for miliary pulmonary infection caused by
M. xenopi even in an immunocompromised patient.
Further clinical studies on the pathophysiology related
to M. xenopi miliary infection are needed in order to
improve the management of this rare condition.
Conclusion
M. xenopi infection should be considered in the differen-
tial diagnosis of miliary pulmonary nodules, even when
the clinical and radiological disease manifestations are
similar to those of miliary tuberculosis.
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